Ö. Soyluk Selçukbiricik Et Al. , "Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma," 22 nd European Congress of Endocrinology (ECE) 2020 , pp.1-3, 2020
Soyluk Selçukbiricik, Ö. Et Al. 2020. Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma. 22 nd European Congress of Endocrinology (ECE) 2020 , 1-3.
Soyluk Selçukbiricik, Ö., Bingöl, Z., Çiftçi, S., Kurtulmuş, N., Tanrıkulu, S., & Yarman, E. S., (2020). Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma . 22 nd European Congress of Endocrinology (ECE) 2020 (pp.1-3).
Soyluk Selçukbiricik, Özlem Et Al. "Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma," 22 nd European Congress of Endocrinology (ECE) 2020, 2020
Soyluk Selçukbiricik, Özlem S. Et Al. "Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma." 22 nd European Congress of Endocrinology (ECE) 2020 , pp.1-3, 2020
Soyluk Selçukbiricik, Ö. Et Al. (2020) . "Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma." 22 nd European Congress of Endocrinology (ECE) 2020 , pp.1-3.
@conferencepaper{conferencepaper, author={Özlem SOYLUK SELÇUKBİRİCİK Et Al. }, title={Optimal cumulative dose of cabergoline does not appear to cause fibrotic pulmonary side effects in prolactinoma}, congress name={22 nd European Congress of Endocrinology (ECE) 2020}, city={}, country={}, year={2020}, pages={1-3} }